Publishes Pivotal Study on Vitiligo Recurrence in the British Journal of Dermatology (BJD)

The Vitiligo Pigment Research Center is proud to announce a significant academic achievement. A research team led by our Center Director, Dr. Chau Yee Ng (MD, PhD), has successfully identified key risk factors for vitiligo recurrence. This extensive retrospective study has been accepted for publication in the British Journal of Dermatology (BJD), ranked among the top three dermatology journals globally.

Key Findings: Achieving repigmentation is a major milestone in vitiligo treatment; however, maintaining stability remains a challenge. The team tracked 809 patients with non-segmental vitiligo who had achieved disease stability. The study revealed:

1. Recurrence Rate: Approximately 1 in 3 patients experienced recurrence or progression after a period of stability.

2. Major Risk Factors:

   • Acral Vitiligo: Lesions located on the hands and feet.

   • Comorbid Thyroid Disease: Particularly autoimmune thyroiditis.

   • Autoimmune Profile: Presence of other autoimmune diseases or positive immune markers (e.g., ANA, Anti-TPO).

3. Combined Risk: Patients presenting with both "Acral Vitiligo" and "Thyroid Disease" face a 2.5-fold increased risk of recurrence.

Clinical Implications: This study underscores that vitiligo recurrence is closely linked to the patient's underlying immune profile. Dr. Ng emphasizes that for high-risk groups, the treatment paradigm must shift from "repigmentation" to "long-term stabilization." The center recommends Maintenance Therapy—such as low-frequency topical applications or intermittent phototherapy—along with regular follow-ups to mitigate the risk of relapse.

Acknowledgments: We extend our sincere gratitude to Dr. Hsin-Yu, Dr. Han-Wen, and Nurse Yi-Ching for their dedication to data collection and statistical analysis. The Vitiligo Pigment Research Center remains committed to advancing clinical research and providing world-class, evidence-based care for vitiligo patients.